Amongst the samples tested for Ranitidine and Nizatidine, the Company is pleased to note that majority of the marketed products in the US that were found within the acceptable limits were manufactured with the APIs supplied by Solara. The company is a key supplier of Ranitidine Hydrochloride 8L Nizatidine API and partners with global pharmaceutical companies for their formulations.

The Company is engaging with its formulation partners to understand the next steps and will provide an update in the next few days.